12:00 AM
 | 
Jul 12, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vidaza azacitidine regulatory update

FDA issued a new quarterly report on safety information emerging from its Adverse Events Reporting System (AERS) during 1Q10 in...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >